Get the Stockscreener App
48.54
10.77%
4.72
Pre-market:
48.73
0.19
+0.39%
Veracyte Inc stock is traded at $48.54, with a volume of 2.88M.
It is up +10.77% in the last 24 hours and up +17.05% over the past month.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
See More
Previous Close:
$43.82
Open:
$43.66
24h Volume:
2.88M
Relative Volume:
2.15
Market Cap:
$3.90B
Revenue:
$541.74M
Net Income/Loss:
$88.01M
P/E Ratio:
44.69
EPS:
1.0862
Net Cash Flow:
$155.34M
1W Performance:
+19.65%
1M Performance:
+17.05%
6M Performance:
+47.36%
1Y Performance:
+48.53%
1-Day Range:
$43.51
$48.95
1-Week Range:
$39.40
$48.95
52-Week Range:
$29.45
$60.91
Veracyte Inc Stock (VCYT) Company Profile
Name
Veracyte Inc
Sector
Industry
Phone
(650) 243-6300
Address
6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VCYT vs TMO, DHR, NTRA, A, IQV
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VCYT
Veracyte Inc
|
48.54 | 3.90B | 541.74M | 88.01M | 155.34M | 1.0862 |
TMO
Thermo Fisher Scientific Inc
|
678.39 | 250.83B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
223.77 | 157.31B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
408.79 | 58.92B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
172.84 | 48.73B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
275.02 | 45.27B | 16.63B | 1.39B | 2.12B | 8.0674 |
Veracyte Inc Stock (VCYT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | Jefferies | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Underweight |
| Oct-20-25 | Initiated | Canaccord Genuity | Hold |
| Mar-20-25 | Initiated | Craig Hallum | Buy |
| Dec-05-24 | Downgrade | Goldman | Buy → Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-16-24 | Initiated | UBS | Buy |
| Oct-10-24 | Initiated | Guggenheim | Buy |
| Feb-23-24 | Reiterated | Needham | Buy |
| Jan-18-23 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-07-22 | Initiated | Stephens | Overweight |
| Nov-18-21 | Resumed | Goldman | Buy |
| Jun-15-21 | Initiated | Raymond James | Outperform |
| Feb-18-21 | Resumed | Needham | Buy |
| Jan-28-21 | Initiated | Truist | Buy |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Sep-09-20 | Initiated | Morgan Stanley | Underweight |
| Jul-31-19 | Initiated | Lake Street | Buy |
| Jul-02-19 | Initiated | Needham | Buy |
| Nov-29-18 | Downgrade | Janney | Buy → Neutral |
| Oct-31-18 | Upgrade | Janney | Neutral → Buy |
| Nov-07-17 | Downgrade | Janney | Buy → Neutral |
| Nov-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-31-17 | Resumed | BTIG Research | Buy |
| Nov-14-16 | Resumed | Leerink Partners | Outperform |
| Dec-18-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-11-15 | Reiterated | Leerink Partners | Outperform |
| Nov-26-13 | Initiated | William Blair | Outperform |
View All
Veracyte Inc Stock (VCYT) Latest News
Veracyte stock rises 10.77 percent toward its yearly high - AD HOC NEWS
Is Veracyte Inc (VCYT) Overvalued After 10.8% Rally? GF Value Sa - gurufocus.com
A Veracyte (VCYT) director plans a $352,500 share sale after selling 5,000 shares. - Stock Titan
Veracyte, Inc. (VCYT) Stock Forecasts - Yahoo! Finance Canada
Understanding Momentum Shifts in (VCYT) - Stock Traders Daily
Veeva Unveils Falcon Router to Streamline Biopharma Case Routing - Zacks Investment Research
Veracyte global chief commercial off. John Leite sells $160,600 stock By Investing.com - Investing.com South Africa
Insider Sell: Global Chief Commercial Officer John Leite Sells 4 - gurufocus.com
Form 4 Veracyte Inc For: 23 September By Investing.com - Investing.com Australia
Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets - TradingView
A Look at Veracyte Inc (VCYT) After 4.4% Gain -- GF Value $39.14 vs Price $41.52 - gurufocus.com
Veracyte (NASDAQ: VCYT) officer to sell 4,015 shares under Rule 144 - Stock Titan
Veracyte (NASDAQ:VCYT) Offers Affordable Growth Backed by Strong Health and Cash Flow - ChartMill
Piper Sandler Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $54 - Moomoo
Veracyte Inc. (NASDAQ: VCYT) Director Holstein Jens Disposes 5,000 Shares at $40.95 Each - Kalkine Media
Veracyte (VCYT) Dropped, But What Is Driving Attention Now? - simplywall.st
Director Jens Holstein Sells 5,000 Shares of Veracyte (VCYT) - gurufocus.com
A Look at Veracyte Inc (VCYT) After 4.1% Decline -- GF Value $39 - gurufocus.com
Veracyte Director Jens Holstein Executes Sale of 5,000 Shares Under 10b5-1 Plan - Kalkine Media
Veracyte (VCYT) director offloads 5,000 shares under plan - Stock Titan
Craig-Hallum Maintains Veracyte(VCYT.US) With Buy Rating - Moomoo
Veracyte Adds Another Stream to Bladder Franchise, UBS Says - marketscreener.com
Veracyte at Morgan Stanley conference: growth, deals and new tests By Investing.com - Investing.com Nigeria
Veracyte at Morgan Stanley conference: growth, deals and new tests - Investing.com
Needham reiterates Veracyte stock rating at Buy on genomics deal By Investing.com - Investing.com Nigeria
Needham Maintains Veracyte(VCYT.US) With Buy Rating, Maintains Target Price $69 - Moomoo
Needham reiterates Veracyte stock rating at Buy on genomics deal - Investing.com
Veracyte acquires Convergent Genomics for up to $180 million By Investing.com - Investing.com Australia
VCYT Looks 5.7% Overvalued on GF Value™ as Insider Selling Persi - GuruFocus
VCYT Looks 5.7% Overvalued on GF Value™ After Convergent Genomics Acquisition - GuruFocus
Veracyte acquires Convergent Genomics for up to $180 million - Investing.com
Veracyte Buys Convergent Genomics - marketscreener.com
Veracyte Acquires Convergent Genomics, Expanding its Urology Diagnostics Portfolio with a Urinary Tumor DNA Testing Platform - marketscreener.com
Press Release: Veracyte Acquires Convergent Genomics, Expanding Its Urology Diagnostics Portfolio With a Urinary Tumor DNA Testing Platform - Moomoo
Veracyte (NASDAQ: VCYT) director to sell $204,747 in shares - Stock Titan
Veracyte, Inc. acquired Convergent Genomics, Inc for $180 million. - marketscreener.com
Veracyte (VCYT) Gets a Buy from UBS - theglobeandmail.com
Zacks Industry Outlook Highlights Veracyte, Globus Medical and UFP Technologies - Yahoo Finance
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tel - GuruFocus
VCYT Maintains Buy Rating by UBS -- Price Target Raised to $65 - GuruFocus
UBS Adjusts Price Target on Veracyte to $65 From $52, Keeps Buy Rating - marketscreener.com
Veracyte CFO Rebecca Chambers Forfeits 3,603 Shares at $44.88 and Sells Additional Shares in Early September - Kalkine Media
VERACYTE Executive Leite John Forfeits 3,961 Shares at $44.88 Each (NASDAQ: VCYT) - Kalkine Media
VERACYTE (NASDAQ: VCYT) Officer Jonathan Wygant Forfeits 1,361 Shares at $44.88 Each - Kalkine Media
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline - Eastern Progress
Chief Scientific & Medical Officer Of Veracyte Sold 33% Of Their Shares - simplywall.st
Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares By Investing.com - Investing.com Australia
Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock By Investing.com - Investing.com South Africa
Veracyte chief scientific & med officer sells over $564k stock - Investing.com Nigeria
Veracyte EVP, general counsel Annie McGuire sells over $140,000 in stock - Investing.com Nigeria
Veracyte chief scientific & med officer sells over $564k stock By Investing.com - Investing.com South Africa
Veracyte Inc Stock (VCYT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Veracyte Inc Stock (VCYT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Leite John | Global Chief Commercial Off |
Sep 21 '26 |
Sale |
40.00 |
4,015 |
160,600 |
124,329 |
1.54%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):